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Background: Exhaled NO (FENO) is a steroid dose dependent eosinophilic inflammometer, but
also a mediator of bronchomotor tone, but statistically significant relationships have infre-
quently been obtained with pulmonary function tests (PFT). The aim was to test the hypothesis
that the relationships between FENO and PFT could be uncovered by inhaled corticosteroid
(ICS) treatment, namely that a link between FENO and bronchodilator response (an index of
bronchomotor tone) would appear under ICS.
Methods: Exhaled NO, forced expiratory flows and lung volumes were measured in atopic asth-
matic children without recent (one month) respiratory symptoms.
Results: Two hundred and thirty children (mean SD, age: 11.2 2.5 years, 69 girls) were
included (% predicted, FEV1: 100  14; FEF50%: 76  23; RV: 107  29). The relationship
between ICS dose (GINA classification) and FENO plateaued in children with an ICS dose higher
than 200 mg beclomethasone equipotent daily dose: FENO (median [25the75th percentiles]),
43 ppb [15e105] (no treatment, nZ 65), 33 ppb [15e77] (low dose, nZ 70), 23 ppb [12e57]
(medium dose, nZ 57) and 26 ppb [9e49] (high dose, nZ 38). Statistically significant relation-
ships between FENO and PFT were only observed in children receiving more than 200 mg/dayPhysiologie e Clinique de la Dyspne´e, Hoˆpital Europe´en Georges Pompidou, 20, rue Leblanc; 75015
.
x@egp.aphp.fr (C. Delclaux).
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946 B. Mahut et al.ICS: with FEV1 (medium ICS dose: rZ 0.43, pZ 0.001; high dose: rZ 0.32, pZ 0.052) and
bronchodilator (400 mg salbutamol) response (medium dose: rZ 0.54, pZ 0.001; high dose:
rZ 0.65, pZ 0.002).
Conclusions: A positive correlation between FENO and bronchomotor tone appears with
increasing ICS doses in atopic children with clinically controlled asthma, which further suggests
that children depicting the highest FENO values may have lesser steroid sensitivity.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
It is well known that inhaled corticosteroid (ICS) admin-
istration reduces exhaled NO fraction (FENO) in steroid-
naı¨ve subjects, and a doseeeffect relationship has been
observed in some studies.1,2 These latter studies, based
on a limited number of patients, also showed a plateau
effect of ICS on FENO.
1,2 Although FENO and sputum or
bronchial eosinophils positively correlated in several
studies,3,4 Jatakanon and colleagues reported a dissocia-
tion between FENO and sputum eosinophils with increasing
dose of budesonide.1 Other studies have also shown
conflicting responses between exhaled NO and eosinophils
under ICS treatment.5,6 This delinking challenges the
concept of exhaled NO as an ‘‘inflammometer’’ reflecting
the eosinophilic inflammation and suggests that
the increase in exhaled NO in asthma could also be
related to other mechanisms. Accordingly, NO is a bron-
choprotective mediator via its production by constitutive
NO synthases (1 and/or 3).7 The ability of exhaled NO
measurement to assess this beneficial property is
uncertain.
The absence of relationship between FENO and baseline
pulmonary function tests is the rule. Nevertheless, using
partitioning of exhaled NO in its proximal and distal sour-
ces, we were able to describe correlations between the
distal source of NO and airflow limitation in asthmatic
children under ICS treatment.4,8
Taking together, it seems realistic to suppose that the
increase in exhaled NO due to allergic inflammation hides
the contribution of constitutive NO synthases. Since steroid
response is related to the down-regulation of epithelial
inducible NO synthase 2, we hypothesized that the rela-
tionships between exhaled NO and bronchomotor tone
would appear with increasing ICS doses. Our aim was
therefore to describe in atopic children with clinically
controlled asthma the relationships between exhaled NO
and both airflow limitation and bronchodilator response,
the latter being an indirect index of an increased bron-
chomotor tone.
Methods
Design of the study
We and other previously demonstrated that the main
factors influencing FENO in asthmatic children are atopy,
allergic exposure and recent upper or lower symptoms.3,9
Consequently, a homogenous group of asthmatic children
was studied: atopic children with clinically controlledasthma, i.e. without any recent symptoms were enrolled at
winter time (to reduce the effect of seasonal allergen
exposure). We further made subgroups of children
according to ICS dose categories defined by GINA
classification.10
Patients
Consecutive children with an established asthma, based
on standard criteria (episodic symptoms of airflow
obstruction are present, airflow obstruction is at least
partially reversible and alternative diagnoses are
excluded10) were eligible if they were addressed for
pulmonary function testing for the regular follow-up of
their asthma, if they were atopic based on previous skin
prick tests (usual perennial allergens [Dermatophagoides
pteronnysinus, Dermatophagoides farinae, Alternariae,
dog, cat] and seasonal allergens [grass, olea, betula,
fagaceae, weeds]), and if their asthma was clinically
controlled for at least one month (absence of recent
exacerbation, absence of any respiratory symptom
[asthma control criteria of GINA guidelines, excepting
lung function10]). Their treatment during the last three
months was recorded (all children were treated). Children
and their parents were informed of the prospective data
recording, and our local ethical committee approved the
protocol.
Exhaled NO (FENO,0.05)
Exhaled NO was measured online, using the Nitric Oxide
Analyzer (NIOX; Aerocrine AB; Solna, Sweden: measure-
ment at a constant 50 mL/s expiratory flow rate: FENO,0.05).
Measurements were performed according to the ERS/ATS
guidelines before lung function tests.11
Pulmonary function tests (PFT)
All PFT were performed without inhaled treatment (bron-
chodilator or long-acting bronchodilator/ICS association) on
the day of the measurement by the same operator (BM).
Spirometry and plethysmographic measurement of specific
airway resistance and thoracic gas volume were performed
according to international guidelines and as previously
described.12 The bronchodilator response (to salbutamol
400 mg) was assessed in children with FEF25e75%< 70% pre-
dicted, and was evaluated according to international
recommendations.13 Reference values were based on
equations edited by Zapletal and Samanek,14 as commonly
done in Europe.15
Table 1 Characteristics of the 230 atopic children.
Variable Baseline
characteristics
n or mean SD nZ 230
Sex (girl/boy) 69/161
Age, years 11.2 2.5
Height, cm 147 15
Atopic dermatitis 111
Early onset of wheezinga 110
Prick skin tests
One positive test 71
More than one 159
Treatment during the last three months
No ICS treatment
(beta-agonist on demand)
65
Budesonide dose/day (n) 317 182 (97)
Fluticasone, dose/day (n) 260 147 (68)
Long-acting beta-agonist 155
Pulmonary function tests (% predicted)
FEV1, % predicted 100 14
FEV1/FVC, % 78 8
FVC, % predicted 106 12
FEF50%, % predicted 76 23
sRaw, % predicted 180 47
TLC, % predicted 105 11
FRC, % predicted 106 16
RV, % predicted 107 29
RV/TLC 0.24 0.06
a >3 Episodes before 2 years of age.
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Since FENO values are not normally distributed they were
expressed as median [25the75th percentiles]. Normally
distributed variables were expressed as mean SD. Corre-
lations between continuous variables were assessed using
Spearman correlation coefficient. Intergroup comparisons
of FENO values were made using non-parametric test
(Kruskal Wallis, Mann Whitney, as appropriate) while
comparisons of PFT parameters were made using Student t
test. A P value <0.05 was regarded as significant. Statistical
analyses were performed using Statview software.Figure 1 Relationships between the equipotent daily dose of
ICS and FENO. Upper panel: Beclomethasone equipotent dose
(dose of fluticasoneZ 1.6 dose of budesonide) is a contin-
uous variable. Lower panel: Beclomethasone equipotent dose
was calculated according to GINA guidelines,10 as in adult
patients (fluticasoneZ 1.6 dose of budesonide) because we
previously suggested that their potency was different on
exhaled NO values,9 a result that is further evidenced in this
study (see Section 3). The ICS dose categories are: no ICS and
low, medium, high ICS doses (the number of patients in each
category is provided). All categories are significantly different
from each other excepting medium and high doses. Box and
whisker plots show the median, 25th and 75th percentiles and
10th and 90th percentiles. Circles are over layers.Results
During the study period (between October 1st 2008 and
March 1st 2009), 230 asthmatic children were included,
whose baseline characteristics are described in Table 1.
Although children treated with fluticasone received
lower doses than children treated with budesonide
(260 147, nZ 97 versus 317 183 mg/day, nZ 68;
p< 0.0001), their FENO was significantly lower (22 ppb [14e
32] versus 30 ppb [19e40], pZ 0.02). Therefore, we used
the equivalence dose of fluticasoneZ 1.6 dose of bude-
sonide in the subsequent analyses (as in adults) and as
previously done in children.9Subgroups of asthmatic children according to ICS
doses
The relationships between FENO and equipotent ICS dose is
illustrated Fig. 1. When grouping patients according to ICS
categories of GINA classification, a doseeeffect of ICS is
demonstrated from no ICS to medium dose of ICS, and then
the FENO values plateaued.
Relationships between FENO and PFT
The statistical significance of the relationships between
FENO and PFT parameters depends on the dose of inhaled
steroid. Fig. 2 shows the relationships between FENO and
FEV1, which are significant in the children receiving
more than 200 mg/day beclomethasone equipotent dose
Figure 2 Relationships between FENO and FEV1 according to the different categories of ICS doses (GINA classification) in the
whole population. Children were grouped according to ICS dose categories defined by GINA guidelines: no ICS (nZ 65), low ICS dose
(nZ 70), medium dose (nZ 57) and high dose (nZ 38).
948 B. Mahut et al.only. A statistically significant relationship between
hyperinflation criteria (RV% predicted, RV/TLC) and FENO
was evidenced in children under high ICS dose only
(pZ 0.028, pZ 0.024; respectively). The statisticalFigure 3 Relationships between FENO and bronchodilator respons
sification) in the 147 who had a bronchodilation test. Children we
guidelines: no ICS (nZ 41), low ICS dose (nZ 42),mediumdose (nZ
thepercentage of increase in FEV1 as compared to baseline FEV1 aftersignificance of all these relationships was lost after
bronchodilation (data not shown), suggesting that the
relationships were related to an increased bronchomotor
tone. This latter result is also sustained by the positivee according to the different categories of ICS doses (GINA clas-
re grouped according to ICS dose categories defined by GINA
40) andhighdose (nZ 24). Bronchodilator (BD) response denotes
rapid-acting bronchodilator administration (salbutamol 400 mg).
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(Fig. 3).Discussion
The main result of this cross-sectional study is to demon-
strate that statistically significant correlations can be evi-
denced between FENO and pulmonary function tests in
atopic children with clinically controlled asthma only when
patients received more than 200 mg beclomethasone equi-
potent daily dose of ICS.
Many studies previously demonstrated that ICS reduces
exhaled NO values, but few studies established a dosee
effect relationship. Jatakanon and colleagues examined
the dose response of inhaled budesonide in a parallel group
design, a plateau response of FENO was found at a dose of
400 mg/day1; quite similarly Silkoff and colleagues using
a single-cohort design demonstrated a doseeeffect rela-
tionship of ICS on FENO without any significant difference
between the two highest ICS doses (400 and 800 mg/day
beclomethasone dipropionate).2 Pijnenburg and colleagues
did not also find any difference in FENO when increasing
budesonide from 800 to 1200 mg daily dose in asthmatic
children.16 Our study was not designed for the demonstra-
tion of a doseeeffect relationship, but provides the ranges
of FENO values according to ICS dose, and further suggests
that exhaled NO values in the highest ranges may reflect
the activity of steroid unresponsive NO synthases, either
due to up-regulated constitutive NO synthase activity and/
or steroid-resistant NO synthase 2 activity.
Previous studies have often failed to demonstrate
a relationship between FENO and airflow limitation, which
may be related to the absence of ICS treatment and/or too
variable ICS doses.3,17 On the opposite the relationship
between exhaled NO and bronchodilator response in atopic
patients has previously been shown.18 The correlation
between FENO and airflow limitation/bronchodilator
response in children with medium to high ICS dose in our
study may suggest that exhaled NO is linked to the
increased bronchomotor tone characterizing the more
severe patients. Since ‘‘normal’’ (>80% predicted) values
of FEV1 are usually encountered in asthmatic children,
19
bronchodilator response was easily tested (based on
FEF25-75%). Nevertheless, bronchodilator response was
assessed on FEV1, according to recommendations.
13 Inter-
estingly, the presence of an airflow limitation sensitive to
bronchodilation despite regular treatment while the clin-
ical status is controlled, which traduces an increased
bronchomotor tone, has previously been used as a func-
tional definition of steroid resistance and/or poor sensi-
tivity.20 Whether the children with the highest FENO values,
according to ICS dose, are depicting some degree of steroid
unresponsiveness (or non-observance) deserves to be
further studied.
Our study has limitations. The bronchodilator response
was not tested in all children (even if it was easily tested).
Moreover, the way of expressing the bronchodilator
response (compared to baseline value, as recom-
mended13) is influenced by the degree of baseline lung
function, which may have increased the significance of
our relationships. Finally, the statistical relationships thatare demonstrated (FENO and increased bronchomotor
tone) do not make causality.
In conclusion, the relationships between airflow limita-
tion/bronchodilator response and exhaled NO are critically
dependent on ICS treatment. The increased bronchomotor
tone and the airflow limitation that are evidenced in the
children with the highest FENO values under ICS may suggest
that exhaled NO may constitute a non-invasive biomarker of
lesser steroid sensitivity.
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